Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 5
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice J. Venom. Anim. Toxins incl. Trop. Dis.
Borborema,Samanta Etel Treiger; Osso Junior,João Alberto; Andrade Junior,Heitor Franco de; Nascimento,Nanci do.
Abstract Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by the protozoan Leishmania spp. Pentavalent antimonial agents have been used as an effective therapy, despite their side effects and resistant cases. Their pharmacokinetics remain largely unexplored. This study aimed to investigate the pharmacokinetic profile of meglumine antimoniate in a murine model of cutaneous leishmaniasis using a radiotracer approach. Methods: Meglumine antimoniate was neutron-irradiated inside a nuclear reactor and was administered once intraperitoneally to uninfected and L. amazonensis-infected BALB/c mice. Different organs and tissues were collected and the total antimony was measured. Results: Higher antimony levels were found in infected than...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Cutaneous leishmaniasis; Meglumine antimoniate; Pharmacokinetics; Biodistribution; Antimony; Radioisotope.
Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992019000100304
Imagem não selecionada

Imprime registro no formato completo
In Vitro antileishmanial properties of neutron-irradiated meglumine antimoniate BABT
Borborema,Samanta Etel Treiger; Andrade Junior,Heitor Franco de; Osso Junior,João Alberto; Nascimento,Nanci do.
Pentavalent antimony, as meglumine antimoniate (Glucantime® ) or sodium stibogluconate (Pentostam® ), is the main treatment for leishmaniasis, a complex of diseases caused by the protozoan Leishmania, and an endemic and neglected threat in Brazil. Despite over half a century of clinical use, their mechanism of action, toxicity and pharmacokinetic data remain unknown. The analytical methods for determination of antimony in biological systems remain complex and have low sensitivity. Radiotracer studies have a potential in pharmaceutical development. The aim of this study was to obtain a radiotracer for antimony, with suitable physical and biological properties. Meglumine antimoniate was neutron irradiated inside the IEA-R1 nuclear reactor, producing two...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Meglumine antimoniate; Leishmaniasis; Leishmania (L.) chagasi; Radiotracer.
Ano: 2005 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132005000700009
Imagem não selecionada

Imprime registro no formato completo
Novel methods for the encapsulation of meglumine antimoniate into liposomes BJMBR
Frézard,F.; Michalick,M.S.M.; Soares,C.F.; Demicheli,C..
The antimonial drug, meglumine antimoniate, was successfully encapsulated in dehydration-rehydration vesicles and in freeze-dried empty liposomes (FDELs). High encapsulation efficiencies (from 28 to 58%) and low weight ratios of lipids to encapsulated antimony (from 1:0.15 to 1:0.3) were achieved. These formulations, contrary to those obtained by conventional methods, can be stored as intermediate lyophilized forms and reconstituted just before use. The efficacy of FDEL-encapsulated meglumine antimoniate was evaluated in hamsters experimentally infected with Leishmania chagasi. A significant reduction of liver parasite burdens was observed in animals treated with this preparation, when compared to control animals treated with empty liposomes. In contrast,...
Tipo: Info:eu-repo/semantics/other Palavras-chave: Liposomes; Glucantime; Meglumine antimoniate; Leishmaniasis; Encapsulation.
Ano: 2000 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000700016
Imagem não selecionada

Imprime registro no formato completo
Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate BJMBR
Schettini,D.A.; Costa Val,A.P.; Souza,L.F.; Demicheli,C.; Rocha,O.G.F.; Melo,M.N.; Michalick,M.S.M.; Frézard,F..
The aim of the present study was to evaluate the impact of a multiple dose regimen of a liposomal formulation of meglumine antimoniate (LMA) on the pharmacokinetics of antimony in the bone marrow of dogs with visceral leishmaniasis and on the ability of LMA to eliminate parasites from this tissue. Dogs naturally infected with Leishmania chagasi received 4 intravenous doses of either LMA (6.5 mg antimony/kg body weight, N = 9), or empty liposomes (at the same lipid dose as LMA, N = 9) at 4-day intervals. A third group of animals was untreated (N = 8). Before each administration and at different times after treatment, bone marrow was obtained and analyzed for antimony level (LMA group) by electrothermal atomic absorption spectrometry, and for the presence of...
Tipo: Info:eu-repo/semantics/other Palavras-chave: Liposome; Meglumine antimoniate; Pharmacokinetics; Leishmaniasis; Dogs; Bone marrow.
Ano: 2005 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200017
Imagem não selecionada

Imprime registro no formato completo
Distribution of liposome-encapsulated antimony in dogs BJMBR
Schettini,D.A.; Costa Val,A.P.; Souza,L.F.; Demicheli,C.; Rocha,O.G.F.; Melo,M.N.; Michalick,M.S.M.; Frézard,F..
The achievement of complete cure in dogs with visceral leishmaniasis is currently a great challenge, since dogs are the main reservoir for the transmission of visceral leishmaniasis to humans and they respond poorly to conventional treatment with pentavalent antimonials. In order to improve the efficacy of treatment, we developed a novel formulation for meglumine antimoniate based on the encapsulation of this drug in freeze-dried liposomes (LMA). The aim of the present study was to evaluate the biodistribution of antimony (Sb) in dogs following a single intravenous bolus injection of LMA. Four healthy male mongrel dogs received LMA at 3.8 mg Sb/kg body weight and were sacrificed 3, 48 and 96 h and 7 days later. Antimony was determined in the blood, liver,...
Tipo: Info:eu-repo/semantics/other Palavras-chave: Liposomes; Meglumine antimoniate; Biodistribution; Leishmaniasis; Dogs.
Ano: 2003 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000200015
Registros recuperados: 5
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional